Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 23.79% is 11% below its 5-year average of 26.66%, around the middle of its 5-year range (0.56%–77.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 192.03% above its 12-month average of 8.15%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 23.79%.
DEBT TO ASSETS RATIO
23.79%
DEBT TO ASSETS RATIO AVG TTM
8.15%
DEBT TO ASSETS RATIO AVG 3Y
32.33%
DEBT TO ASSETS RATIO AVG 5Y
26.66%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+192.03%
CURRENT VS 3Y AVG
-26.42%
CURRENT VS 5Y AVG
-10.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 806 covered companies
CURRENT VS SECTOR MEDIAN
+26332.45%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$731.24M
Debt to Assets Ratio
23.79%
TTM Avg
8.15%
3Y Avg
32.33%
5Y Avg
26.66%
Market Cap
$737.79M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$726.83M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$723.78M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$717.57M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$750.73M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$712.89M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$703.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$703.33M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $731.24M | 23.79% | 8.15% | 32.33% | 26.66% |
| Faeth Therapeutics, Inc. (FTH)vs › | $737.79M | 0.00% | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $726.83M | 0.08% | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $723.78M | 0.00% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $717.57M | 0.06% | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $750.73M | 0.01% | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $712.89M | 0.40% | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $703.58M | 0.00% | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $703.33M | 0.00% | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.75M | 0.24% | N/A | N/A | N/A |
Debt/Assets
23.8%
Debt/Equity
0.39
Current Ratio
16.09
Interest Coverage
-22.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 23.79% |
| 2026-03-31 | 0.89% |
| 2025-12-31 | 1.52% |
| 2025-09-30 | 6.66% |
| 2025-06-30 | 7.87% |
| 2025-03-31 | 11.38% |
| 2024-12-31 | 12.61% |
| 2024-09-30 | 77.03% |
| 2024-06-30 | 72.12% |
| 2024-03-31 | 67.54% |
| 2023-12-31 | 54.58% |
| 2023-09-30 | 45.49% |
| 2023-06-30 | 38.80% |
| 2023-03-31 | 33.89% |
| 2022-12-31 | 29.04% |
| 2022-09-30 | 26.83% |
| 2022-06-30 | 24.43% |
| 2022-03-31 | 22.44% |
| 2021-12-31 | 0.63% |
| 2021-09-30 | 0.56% |
| 2021-06-30 | 1.69% |
| 2021-03-31 | 2.75% |
| 2020-12-31 | 2.47% |
